Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · Real-Time Price · USD
1.790
+0.060 (3.47%)
At close: Sep 26, 2025, 4:00 PM EDT
1.840
+0.050 (2.79%)
After-hours: Sep 26, 2025, 7:05 PM EDT
3.47%
Market Cap64.35M
Revenue (ttm)n/a
Net Income (ttm)-18.59M
Shares Out 35.95M
EPS (ttm)-0.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume459,292
Open1.740
Previous Close1.730
Day's Range1.690 - 1.792
52-Week Range1.410 - 3.190
Beta0.14
AnalystsStrong Buy
Price Target8.20 (+358.1%)
Earnings DateNov 13, 2025

About GANX

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 18, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol GANX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $8.2, which is an increase of 358.10% from the latest price.

Price Target
$8.2
(358.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...

3 days ago - GlobeNewsWire

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule

8 days ago - GlobeNewsWire

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) me...

22 days ago - GlobeNewsWire

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson's Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biom...

6 weeks ago - GlobeNewsWire

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

2 months ago - GlobeNewsWire

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

2 months ago - GlobeNewsWire

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

2 months ago - GlobeNewsWire

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

As of June 30 th , 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025

3 months ago - GlobeNewsWire

Gain Therapeutics to Participate in Upcoming Investor Conferences

BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

3 months ago - GlobeNewsWire

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...

4 months ago - GlobeNewsWire

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025

4 months ago - GlobeNewsWire

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopamin...

4 months ago - GlobeNewsWire

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...

5 months ago - GlobeNewsWire

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...

5 months ago - GlobeNewsWire

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...

6 months ago - GlobeNewsWire

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025

6 months ago - GlobeNewsWire

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...

7 months ago - GlobeNewsWire

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...

7 months ago - GlobeNewsWire

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

8 months ago - GlobeNewsWire

Gain Therapeutics To Participate in Upcoming Investor Conferences

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

8 months ago - GlobeNewsWire

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug'...

9 months ago - Seeking Alpha

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months ...

9 months ago - GlobeNewsWire

Gain Therapeutics To Present At Biotech Showcase 2025

Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform

10 months ago - GlobeNewsWire

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson's Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson's...

1 year ago - GlobeNewsWire

Gain Therapeutics to Participate at Upcoming Investor Conferences

BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

1 year ago - GlobeNewsWire